Featured Research

from universities, journals, and other organizations

Two-pronged approach successfully targets DNA synthesis in leukemic cells

Date:
February 24, 2014
Source:
The Rockefeller University Press
Summary:
A novel two-pronged strategy targeting DNA synthesis can treat leukemia in mice while sparing damage to normal blood cells, researchers have shown. Current treatments for acute lymphoblastic leukemia (ALL), an aggressive form of blood cancer, include conventional chemotherapy drugs that inhibit DNA synthesis. These drugs are effective but have serious side effects on normal dividing tissues. Results of the new research indicate that there may be other ways to address leukemia while sparing the patient these side effects.

A novel two-pronged strategy targeting DNA synthesis can treat leukemia in mice, according to a study in The Journal of Experimental Medicine.

Current treatments for acute lymphoblastic leukemia (ALL), an aggressive form of blood cancer, include conventional chemotherapy drugs that inhibit DNA synthesis. These drugs are effective but have serious side effects on normal dividing tissues.

In order to replicate, cells must make copies of their DNA, which is made up of building blocks called deoxyribonucleotide triphosphates (dNTPs). Cells can either make dNTPs from scratch (the "de novo" pathway) or by picking up the breakdown products of cells death (the "salvage" pathway). Caius Radu and colleagues at the University of California, Los Angeles now show that blocking the de novo pathway using thymidine causes leukemia cells to switch to the salvage pathway. This may explain why thymidine showed limited effectiveness as a single agent in clinical trials. Blocking both the de novo and salvage pathways was lethal for leukemic cells. The authors also found that a novel small molecule inhibitor of the salvage pathway enzyme deoxycytidine kinase blocked leukemia growth in mice in combination with thymidine (to inhibit the de novo pathway). Importantly, there was no significant toxicity to normal blood cell development. Why leukemic cells and normal blood cell precursors respond so differently to this treatment requires further investigation.

According to Radu, "this new dual targeting approach shows that we can overcome the redundancy in DNA synthesis in ALL cells and identifies a potential target for metabolic intervention in ALL, and possibly in other hematological cancers."

This interdisciplinary study not only advances our understanding of DNA synthesis in leukemic cells but also identifies targeted metabolic intervention as a new therapeutic approach in ALL. Clinical trials will be required to establish whether these promising findings will translate into a new therapeutic approach for ALL.


Story Source:

The above story is based on materials provided by The Rockefeller University Press. Note: Materials may be edited for content and length.


Journal Reference:

  1. D. A. Nathanson, A. L. Armijo, M. Tom, Z. Li, E. Dimitrova, W. R. Austin, J. Nomme, D. O. Campbell, L. Ta, T. M. Le, J. T. Lee, R. Darvish, A. Gordin, L. Wei, H.-I. Liao, M. Wilks, C. Martin, S. Sadeghi, J. M. Murphy, N. Boulos, M. E. Phelps, K. F. Faull, H. R. Herschman, M. E. Jung, J. Czernin, A. Lavie, C. G. Radu. Co-targeting of convergent nucleotide biosynthetic pathways for leukemia eradication. Journal of Experimental Medicine, 2014; DOI: 10.1084/jem.20131738

Cite This Page:

The Rockefeller University Press. "Two-pronged approach successfully targets DNA synthesis in leukemic cells." ScienceDaily. ScienceDaily, 24 February 2014. <www.sciencedaily.com/releases/2014/02/140224123636.htm>.
The Rockefeller University Press. (2014, February 24). Two-pronged approach successfully targets DNA synthesis in leukemic cells. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2014/02/140224123636.htm
The Rockefeller University Press. "Two-pronged approach successfully targets DNA synthesis in leukemic cells." ScienceDaily. www.sciencedaily.com/releases/2014/02/140224123636.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins